Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma

Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma

Survivin is an anti-apoptotic protein that is highly expressed in many cancers, including malignant gliomas. Preclinical studies established that the conjugated survivin peptide mimic SurVaxM (SVN53-67/M57-KLH) could stimulate an anti-tumor immune response against murine glioma in vivo, as well as h...

Full description

Bibliographic Details
Main Authors: Fenstermaker, Robert A., Ciesielski, Michael J., Qiu, Jingxin, Yang, Nuo, Frank, Cheryl L., Lee, Kelvin P., Mechtler, Laszlo R., Belal, Ahmed, Ahluwalia, Manmeet S., Hutson, Alan D.
Format: Online
Language:English
Published: Springer Berlin Heidelberg 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069322/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069322/

Similar Items